Supplementary Figure S3 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
Year: 2026
Type: supplementary-materials
Abstract: Supplementary Figure 3. A representative image of a ccRCC sample from the HCRN GU16-260 clinical trial analyzed by multiplex immunofluorescence for expression of CD20 (B cells), CD3 (T cells), and CD21 (follicular dendritic cells). A mature TLS is identified as an aggregate of B cells admixed with follicular dendritic cells with surrounding T cells
Authors: Nourhan El Ahmar, Morgan A. Paul, Berkay Simsek, Sayed Matar, Opeyemi A. Jegede, Yasmin Nabil Laimon, Varunika Savla, Razan Mohanna, Gabriel Roberti de Oliveira, Aseman Bagheri Sheshdeh, Thomas Denize, Destiny J. West, Maxwell D. Seager, Maxine Sun, Toni K. Choueiri, Wanling Xie, Gordon J. Freeman, Arlene H. Sharpe, David A. Braun, Naomi B. Haas, Hans Hammers, Mehmet A. Bilen, Mark Stein, Jeffrey A. Sosman, Catherine J. Wu, David F. McDermott, Michael B. Atkins, Sabina Signoretti
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7203487898
Cites:
Cited by:
Related to: